Safety and efficacy of everolimus (EVE) plus exemestane (EXE) in postmenopausal women with locally advanced or metastatic breast cancer: final results from EVEREXES

ConclusionThe safety and efficacy results from EVEREXES trial are consistent to data previously reported in BOLERO-2. These results support that EVE + EXE could be a viable treatment option for the postmenopausal women with HR+, HER2 − ABC in Asian region.

http://link.springer.com/10.1007/s10549-021-06173-z

Source: Breast Cancer Research and Treatment - March 16, 2021 Category: Cancer & Oncology Source Type: research